[CAS NO. 2349386-89-4]  Molnupiravir (EIDD-2801)

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2349386-89-4]

Catelog
SLK-S8969
Brand
Selleck
CAS
2349386-89-4

DESCRIPTION [2349386-89-4]

Overview

MDL-
Molecular Weight329.31
Molecular FormulaC13H19N3O7
SMILESCC(C)C(OC[C@H]1O[C@@H](N(C(N/2)=O)C=CC2=N\O)[C@H](O)[C@@H]1O)=O

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM3.0367 mL15.1833 mL30.3665 mL
5 mM0.6073 mL3.0367 mL6.0733 mL
10 mM0.3037 mL1.5183 mL3.0367 mL
50 mM0.0607 mL0.3037 mL0.6073 mL

Description

Molnupiravir (EIDD-2801, MK-4482) is an orally bioavailable prodrug of the ribonucleoside analog β-d-N-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum against , , , and the causative agent of .

Targets

SARS-CoV-2 [1]MERS-CoV [1]SARS-CoV [1]

In vitro

EIDD-2801 is an orally bioavailable NHC-prodrug. NHC is potently antiviral against SARS-CoV-2, MERS-CoV and SARS-CoV in primary human epithelial cell cultures without cytotoxicity. NHC is effective against remdesivir (RDV)-resistant vi-rus and multiple distinct zoonotic CoV. NHC antiviral activity is associated with increased viral mutation rates.